Psoriasis is a chronic inflammatory skin disorder, and current treatments include topical
therapies, phototherapy, systemic immune modulators, and biologics, aiming to alleviate …

Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US
population. This guideline addresses important clinical questions that arise in psoriasis …

This evidence‐and consensus‐based guideline on the treatment of psoriasis vulgaris was
developed following the EuroGuiDerm Guideline and Consensus Statement Development …

Immunotherapy targeting the autoimmune process in type 1 diabetes (T1D) can delay the
loss of β-cells but needs to have minimal adverse effects to be an adjunct to insulin in the …

Psoriasis is a frequent inflammatory skin disease. Fundamental research on the
pathogenesis of psoriasis has substantially increased our understanding of skin …

Background There are limited data to inform positioning of agents for treating moderate‐
severe Crohn's disease (CD). Aim We assessed comparative efficacy and safety of first‐line …

Importance Biologics and targeted therapies, such as apremilast, are efficient treatments to
manage moderate to severe psoriasis. More information about the risk of serious infection is …

Oral systemic therapies are important treatment options for patients with moderate-to-severe
psoriasis, either as monotherapy or in therapy-recalcitrant cases as combination therapy …

Introduction The safety profile of adalimumab was previously reported in 23,458 patients
across multiple indications. Here we report the long-term safety of adalimumab in adults with …

Psoriasis and psoriatic arthritis cause significant physical and psychological burdens for
afflicted individuals. An accelerated TNF-α/IL-23/IL-17 axis is their major pathomechanism; …